LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Clinical Trials

Other Health

Biotechnology

Pharmaceutical

Health

Science

Oncology

Other Science

KMT2A MRD Testing

More Like This

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

U.S. Food and Drug Administration Authorizes CytoCell KMT2A Breakapart FISH Probe Kit PDx as a New Companion Diagnostic for KMT2A rearranged Acute Leukaemia

PR Newswire associated0

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring

PR Newswire associated0

MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®